

ANALYSIS OF EXPENDITURE ON ORPHAN DRUGS ACCORDING TO THE DIAGNOSIS



Carrión Madroñal IM, Selvi Sabater P, Contreras Rey MB, Montero Pérez O, Bocanegra Martín C.
Pharmacy Department. Juan Ramón Jiménez Hospital. Servicio Andaluz de Salud. Huelva. Spain.

2SPD-015
V03-All other therapeutic products

OBJECTIVES

To describe and to analyze the evolution of expenditure on orphan drugs according to the diagnosis.





METHODS

Retrospective study that includes all the patients whom orphan drugs have been dispensed from January 2014 to December 2016. The parameters collected were: number of patients per drug, per diagnosis, and per economic expenditure(€) and percentage to total expenditure, and annual expenditure. The data were obtained from the optimized computerized order entry ATHOS® software and collected on an Excel® database designed for this purpose.

RESULTS

		2014	2015	2016
Total expenditure 2014 - 2016	16.219.960 €			
% of expenditure		29 %	33 %	38 %
Number of patients		252	279	295
Expenditure per patient		18.666 €	19.185 €	20.894 €

Evolution of annual expenditure			
Metabolic Disease	33%	34%	37%
Multiple Myeloma	20%	22%	23%
Oncology Disease	16%	18%	22%
Pulmonary Hypertension	20%	15%	5%
Paroxysmal Nocturnal Hemoglobinuria	7%	6%	6%



CONCLUSION

In the last 3 years, the number of patients with prescribed orphan drugs has increased, with a rise of 1.3 million euro. Metabolic Diseases are one of the biggest expenses every year, with a very small number of patients, and a high cost per patient/year.